Von Willibrand’s Disease: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
[https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-vonvendi-von-willebrand-disease-including-certain-uses-children FDA Approves Expanded Use of Vonvendi for von Willebrand Disease, Including for Certain Uses for Children] | [https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-vonvendi-von-willebrand-disease-including-certain-uses-children FDA Approves Expanded Use of Vonvendi for von Willebrand Disease, Including for Certain Uses for Children] | ||
[https://pubmed.ncbi.nlm.nih.gov/35439298/ Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results] | |||
Revision as of 11:14, 7 October 2025
This is a Stub Notice. This page has not been completed. You can work on this page by signing in and going to the Edit tab. Thanks for helping to make PedsAnesthesia.Net Wiki useful.
Go to the Main Page to see the Topic Outline.
Go to the Generalized Suggested Outline for information on case-specific details for each page.
Go to the Test Page for examples on how to use references in the page.
Relevant Article Depot:
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease